COMPANY
Roen Health, Inc. dba RoenRx
Roen Health, Inc. dba RoenRx: warning letter recipient for Semaglutide, as stated by public registers.
WARNING LETTER RECIPIENT
Received an FDA warning letter naming the peptide.
| Semaglutide | False & Misleading Claims/Misbranded (Telehealth), 2026-06-08 Regulator FDA warning letters |
|---|
What a register states, not an endorsement or an accusation by this site. All companies.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.